Small Stocks, Big Money™

Atossa Therapeutics (Nasdaq: ATOS) unveiled full results from its I-SPY 2 sub-study showing that low-dose (Z)-endoxifen achieved rapid Ki-67 suppression and a 78% median tumor volume reduction, all with a favorable safety profile. With feasibility goals surpassed and strong early biologic activity confirmed, these findings support Atossa’s strategy to escalate dosing in upcoming I-SPY 2 cohorts targeting deeper tumor responses in ER+/HER2- breast cancer.

Connect Biopharma (Nasdaq: CNTB) has initiated its Phase 2 Seabreeze STAT COPD study to evaluate rademikibart—a next-gen IL-4Rα antibody—for acute COPD exacerbations in patients with type 2 inflammation. Backed by prior asthma trial data showing rapid FEV1 improvement and strong safety, this study aims to fill a major unmet need in the $10B+ COPD market, with topline results expected in 1H 2026.

FatPipe (Nasdaq: FATN) has launched a strategic VeloCloud Replacement Program to help enterprises upgrade aging SD-WAN infrastructure with its next-gen, secure platform—featuring zero-cost migration, trade-in discounts, and built-in multi-cloud support. Backed by IPO proceeds and internal funds, the initiative aims to capitalize on a $7B+ SD-WAN market by converting first-gen deployments into long-term, recurring revenue streams across North America and APAC.

XTI Aerospace (Nasdaq: XTIA) has signed an MOU with hybrid-electric propulsion leader VerdeGo Aero to explore integration of next-gen powertrain systems into XTI’s TriFan 600 aircraft and future variants. The collaboration targets high-speed, long-range VTOL solutions for both military and commercial UAS missions—tapping into VerdeGo’s proven hybrid technology to enhance performance, efficiency, and sustainability across critical logistics and cargo applications.